Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

UNLOCKING INNOVATION OPPORTUNITIES IN MECHANOBIOLOGY AND MECHANOMEDICINE

Project description

The most advanced in vitro platform for mechanobiology and mechanomedicine

Pathological conditions are often driven by mechanical changes within tissues, yet existing drug development models generally fail to incorporate these mechanics. This lack of technologies to simulate physiological environments inhibits research and the development of effective therapies. To address this, the EIC-funded NEOMAG project has developed an AI-guided magneto-mechanical platform capable of programming, sensing and controlling the mechanical microenvironment of living tissues. The technology will enable researchers to replicate the physical behaviour of pathologies, from cancerous tumours to damaged tissue and traumatic brain injuries, identify therapeutic targets and design new drugs and therapies. The project now intends to scale up and validate its prototype in preparation for commercial production.

Objective

Mechanical forces critically shape processes such as stem cell differentiation, cancer invasion, and tissue repair, yet most experimental and drug development platforms fail to capture this dimension. The lack of technologies that reproduce physiologically relevant mechanics hinders both fundamental discovery and the design of effective therapies. NeoMag EIC Transition focuses on validating the first AI-guided magneto-mechanical platform that can precisely program, sense, and control the mechanical microenvironment of living tissues under high-resolution microscopy. Our mission: Revolutionize biomedical research to spark new scientific and therapeutic possibilities.
Our integrated hardware will produce stable, high-frequency, spatially resolved deformation fields; calibrated mechanical consumables that translate actuation into reproducible tissue-level cues; and a hybrid physics+AI control stack that learns inverse mappings from desired cellular responses to actuation patterns.
60ND is the lead and UC3M participates as affiliate entity. As a UC3M spin-off, 60ND holds an exclusive license to the UC3M patent, including rights to further develop the technology andits commercialization. The team blends mechanobiology, smart materials, and data/AI with venture and startup experience, ensuring rigorous validation, stakeholder engagement with reference laboratories, and credible post-project pathways.
Initial early adopters that will be pursued during this project are research labs, biotech/pharma, and CROs in organs-on-chip, regenerative medicine, and oncology, segments with clear pain points and strong purchasing power. A RUO-first pathway, an ISO-aligned QMS foundation, and an IP/FTO strategy anchored in our exclusive UC3M license de-risk market entry and scale-up. The result is to validate a compelling venture case: a defensible technology platform, clear unit economics via recurring consumables/software, and a credible path to partnerships and distribution.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2025-TRANSITIONOPEN

See all projects funded under this call

Coordinator

60ND SL
Net EU contribution
€ 2 131 075,70
Address
AVDA GREGORIO PECES-BARBA 1 PARQUE CIENTIFICO
28919 LEGANES
Spain
SME
Yes
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data

Participants (1)